The thesis
channel-pullback is a straightforward trend-continuation strategy: it buys pullbacks to the lower regression channel or volume support within confirmed uptrends, then exits at the upper channel or overhead resistance. The universe is a defensively tilted basket of 24 mega-caps — AAPL, MSFT, NVDA, the payment networks, healthcare, staples, and a few industrials like CAT and HON. It is a "buy strength on weakness" idea, which lives or dies on the regime being genuinely trending rather than choppy.
Recent activity
The strategy is live and trading on schedule. Over the last week of runs (2026-07-08 through 2026-07-15) it executed steadily — 2 to 6 fills per session with zero rejections — and portfolio total value has drifted in a tight band, from $10,333.15 down to $10,026.15. The most recent runs show active rotation: on 2026-07-13 it trimmed six positions (NVDA, GOOGL, WMT, DIS, COST) and added CAT, then over the next two days rotated into PG, UNH, and a re-entry on AAPL while selling an earlier AAPL lot. That is the channel logic at work — taking profits into strength and redeploying into names that have pulled back.
Backtest performance
The headline backtest returns 7.62% total (final equity $10,761.52) over 451 days, a 4.19% CAGR, with a 14.83% max drawdown and a Sharpe of just 0.40. Two numbers deserve attention. First, the win rate is only 39.39% across 137 trades — the strategy is profitable despite losing more often than it wins, meaning it relies on winners being meaningfully larger than losers. That is normal for trend-following, but it makes results sensitive to a handful of big moves. Second, turnover is 2,311% — extremely high churn, which in live trading amplifies slippage and fee drag well beyond the $137 modeled here.
Validation — the sobering part
Walk-forward validation failed. Three of four out-of-sample folds were positive, but the spread is wide: Fold 1 +6.53% (Sharpe 1.25), Fold 3 an excellent +20.68% (Sharpe 3.86), Fold 4 +3.63% — yet Fold 2 (Jan–Jul 2025) lost -11.42% at a -1.70 Sharpe. The out-of-sample composite return of 3.63% is roughly half the full-sample 7.62%, a classic sign of in-sample optimism.
The multiple-testing statistics tell the real story. The Probabilistic Sharpe Ratio is a borderline 0.702, but the Deflated Sharpe Ratio is only 0.196 after accounting for 7 trials — well short of confidence that the edge is real rather than the best of several attempts.
Verdict
channel-pullback has a coherent, well-motivated thesis and executes cleanly in production. But the evidence is mixed: a sub-0.5 Sharpe, a sub-40% win rate, punishing turnover, and — most importantly — a failed validation with one deeply negative fold and a deflated Sharpe near zero. This is a strategy worth keeping in paper trading to gather live evidence, not one to trust with real capital yet. The single-regime dependence exposed by Fold 2 is the risk to watch.